Last reviewed · How we verify
VVN001 Ophthalmic Solution, 5%
VVN001 Ophthalmic Solution, 5% is a corticosteroid that reduces inflammation in the eye.
VVN001 Ophthalmic Solution, 5% is a corticosteroid that reduces inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.
At a glance
| Generic name | VVN001 Ophthalmic Solution, 5% |
|---|---|
| Sponsor | VivaVision Biotech, Inc |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids like VVN001 work by inhibiting the production of pro-inflammatory mediators, thereby reducing swelling and pain in the eye. This is particularly useful for treating conditions such as uveitis and other inflammatory eye diseases.
Approved indications
- Treatment of non-infectious uveitis affecting the posterior segment of the eye
Common side effects
- Increased intraocular pressure
Key clinical trials
- Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease (PHASE3)
- Study of VVN001 Ophthalmic Solution in Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VVN001 Ophthalmic Solution, 5% CI brief — competitive landscape report
- VVN001 Ophthalmic Solution, 5% updates RSS · CI watch RSS
- VivaVision Biotech, Inc portfolio CI